Abstract: There is provided an implant that is safe for the living body. An angular plate as the implant includes a bone supporting plate part and a blade part. The blade part is integrally formed with the bone supporting plate part, and extends from one end of the bone supporting plate part at a predetermined angle ? (0°<?<180°) relative to the bone supporting plate part. The angular plate is formed from a titanium-tantalum-based alloy containing tin. The angular plate is preferably formed from a titanium-tantalum-based alloy containing tin in which a Young's modulus is decreased by increasing the reduction ratio thereof.

Abstract: A medical member of the present invention includes a knitted body knitted with a linear member formed in a linear shape, at least a part of the knitted body is constituted of an alloy containing titanium, tantalum, and tin, and the alloy is constituted of 15 at % to 27 at % of tantalum and 1 at % to 8 at % of tin, where the total is 100 at %, with remainder being titanium and unavoidable impurities. The knitted body is formed in a sheet shape by plain weaving, twilled weaving, plain dutch weaving, twilled dutch weaving, or stockinette stitch. Thus, there can be provided a medical member capable of dispersing a load applied to a treating site of a soft tissue.

Abstract: There is provided an implant that is safe for the living body. An angular plate as the implant includes a bone supporting plate part and a blade part. The blade part is integrally formed with the bone supporting plate part, and extends from one end of the bone supporting plate part at a predetermined angle ? (0°<?<180°) relative to the bone supporting plate part. The angular plate is formed from a titanium-tantalum-based alloy containing tin. The angular plate is preferably formed from a titanium-tantalum-based alloy containing tin in which a Young's modulus is decreased by increasing the reduction ratio thereof.

Abstract: There are provided a treatment agent and a treatment method for physically solidifying an aqueous waste liquid such as a floor wax peeling polluted water and the like simply and also speedily. On an occasion when treating the aqueous waste liquid physically, the treatment agent added to this aqueous waste liquid includes a polymer water-absorbing agent and a dispersing agent which is mixed with a polymer water-absorbing agent in order to disperse this polymer water-absorbing agent in the aqueous waste liquid. By adding this treatment agent to the aqueous waste liquid, the whole of both the substances is solidified into an aggregate of a crushed sponge-like granular material having a size in a range of averagely 0.4 mm to 10 mm.

Abstract: This invention relates to compounds represented by the general formula [I] wherein, R represents an azido group, etc., R1 and R2 are the same or different and represent hydrogen atoms, etc., R3 and R4 are the same or different and represent hydrogen atoms, etc., X1 represents an oxygen atom, etc., X2 represents an oxygen atom, etc., Y represents an oxygen atom, etc., and Z represents a condensed aryl group, etc., or a pharmaceutically acceptable salt thereof, preparation processes thereof, and an agent for treating diabetes, a prophylactic agent for chronic complications of diabetes or a drug against obesity, containing, as an effective ingredient, the compound or the pharmaceutically acceptable salt thereof.

Abstract: This invention relates to compounds represented by the general formula [I] 1

Abstract: This invention relates to compounds represented by the general formula [I]   wherein, R represents an azido group, etc., R1 and R2 are the same or different and represent hydrogen atoms, etc., R3 and R4 are the same or different and represent hydrogen atoms, etc., X1 represents an oxygen atom, etc., X2 represents an oxygen atom, etc., Y represents an oxygen atom, etc., and Z represents a condensed aryl group, etc., or a pharmaceutically acceptable salt thereof, preparation processes thereof, and an agent for treating diabetes, a prophylactic agent for chronic complications of diabetes or a drug against obesity, containing, as an effective ingredient, the compound or the pharmaceutically acceptable salt thereof.

Abstract: An iron-based powder mixture for powder metallurgy, comprising: an iron-based powder, and from 0.05 to 0.50% by weight of a thermoplastic resin powder which comprises 50% or more by weight of units of at least one monomer selected from the group consisting of acrylic esters, methacrylic esters, and aromatic vinyl compounds, and whose average primary particle size is from 0.03 to 5 .mu.m, whose average agglomeration particle size is from 5 to 50 .mu.m, and whose average molecular weight measured by the specific viscosity of a solution is from 30000 to 5000000.

Abstract: An unsaturated polyester resin composition for molding comprising (A) an unsaturated polyester resin, (B) a thickening agent containing powder of a thermoplastic resin as the effective component thereof in an amount of 20 to 120 parts by weight per 100 parts by weight of the unsaturated polyester resin, (C) a liquid polymerizable monomer in an amount of 30 to 120 parts by weight per 100 parts by weight of the unsaturated polyester resin, and (D) a curing agent; SMC and BMC prepared by adding (E) a reinforcing material to the composition; and a process for molding the SMC and the BMC at a low temperature under a low pressure. The unsaturated polyester resin composition of the present invention can be converted into SMC in a short time. The obtained SMC has an excellent storage stability, can be molded at a low temperature under a low pressure, and provides a molded product exhibiting low shrinkage, excellent surface smoothness, a large strength, and a large modulus.

Abstract: A heteroaromatic ring-fused cyclopentene derivative of the formula: ##STR1## wherein the variables are as defined in the specification; or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to compounds which are antagonists of endothelin, to processes for their preparation, and to their use as pharmaceuticals. The compounds of the invention are Useful in the treatment of hypertension, pulmonary hypertension, Reynaud's disease, myocardial infarction, angina pectoris, acute renal failure, cerebral infarction, cerebral vasospasm, arteriosclerosis, asthma, endotoxin shock, endotoxin-induced multiple organ failure or disseminated intravascular coagulation, and/or cyclosporin-induced renal failure or hypertension.

Abstract: An adhesion-reinforcing composition for an epoxy resin adhesive which comprises a copolymer resin particle having been ion-crosslinked with a univalent or divalent metal cation, which particle is comprised of (i) a core ingredient composed of a polymer comprising diene monomer units and optional crosslinking monomer units and having a glass transition temperature not higher than -30.degree. C. and (ii) a shell ingredient composed of a copolymer having a glass transition temperature of at least 70.degree. C. and comprising acrylate or methacrylate monomer units and 0.01-20 wt. parts, per 100 wt. parts of the shell ingredient, of units of a radically polymerizable unsaturated carboxylic acid monomer having a carboxyl group and 3-8 carbon atoms; the core/shell weight ratio being 5/1-1/4. A composition comprising 100 wt. parts of an epoxy resin, 15-60 wt.

Abstract: A process for adhesion using an epoxy rein adhesive composition which comprises coating surfaces for adhesion with a two component epoxy resin adhesive composition prepared immediately before the coating by mixing a mixture containing (A) resin powder prepared by ionic crosslinking of resin particles by addition of a metal cation and (B) an epoxy resin with (C) a curing agent of a room temperature curing type for epoxy resins, bringing the coated surfaces for adhesion into contact with each other, and subsequently heating the surfaces for adhesion. The resin particle is constituted with (a) a core formed with a (meth)acrylate polymer and/or a diene polymer which has a glass transition temperature of -30.degree. C. or lower and (b) a shell formed with a copolymer of a (meth)acrylate monomer and a radical polymerizable unsaturated carboxylic acid monomer having carboxyl group and 3 to 8 carbon atoms which has a glass transition temperature of 70.degree. C. or higher.

Abstract: Peptides having the formula: ##STR1## inhibit the binding of endothelin to its ET.sub.B receptor and are useful in treating diseases associated with excess production or secretion of endothelin.

Abstract: Peptides having the formula: ##STR1## inhibit the binding of endothelin and are useful in treating diseases associated with excess production or secretion of endothelin.

Abstract: Peptides having the formula: ##STR1## inhibit the binding of endothelin to its receptor and are useful in treating diseases associated with excess production or secretion of endothelin.

Abstract: Peptides having the formula ##STR1## inhibit the binding of endothelin to its receptor and are useful in treating diseases associated with excess production or secretion of endothelin.

Abstract: A heteroaromatic ring-fused cyclopentene derivative of the formula: ##STR1## wherein the variables are as defined in the specification; or a pharmaceutically acceptable salt thereof.

Abstract: A guanidinobenzene derivative represented by the formula (I): ##STR1## wherein R.sup.1 represents a substituent selected from the group consisting of a phenyl group substituted by an amidino group and a naphthyl group substituted by an amidino group, and salt thereof; a process for the production thereof; and an antiviral pharmaceutical composition comprising the compound.

Abstract: There is provided a tubular connector to connect first and second fluid tubes wherein separately formed first and second tubular sections are jointed together with a built-in artificial valve in the inside fluid path.